Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 31998R0613

    Commission Regulation (EC) No 613/98 of 18 March 1998 amending Annexes II, III and IV of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance)

    IO L 82, 19.3.1998, p. 14–17 (ES, DA, DE, EL, EN, FR, IT, NL, PT, FI, SV)

    Foilsíodh an doiciméad seo in eagrán speisialta (CS, ET, LV, LT, HU, MT, PL, SK, SL, BG, RO)

    Legal status of the document No longer in force, Date of end of validity: 05/07/2009; Arna aisghairm go hintuigthe ag 32009R0470

    ELI: http://data.europa.eu/eli/reg/1998/613/oj

    19.3.1998   

    EN

    Official Journal of the European Communities

    L 82/14


    COMMISSION REGULATION (EC) No 613/98

    of 18 March 1998

    amending Annexes II, III and IV of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin

    (Text with EEA relevance)

    THE COMMISSION OF THE EUROPEAN COMMUNITIES,

    Having regard to the Treaty establishing the European Community,

    Having regard to Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (1), as last amended by Commission Regulation (EC) No 426/98 (2) and in particular Articles 6 and 8 thereof,

    Whereas, in accordance with Regulation (EEC) No 2377/90, maximum residue limits must be established progressively for all pharmacologically active substances which are used within the Community in veterinary medicinal products intended for administration to food-producing animals;

    Whereas maximum residue limits should be established only after the examination within the Committee for Veterinary Medicinal Products of all the relevant information concerning the safety of residues of the substance concerned for the consumer of foodstuffs of animal origin and the impact of residues on the industrial processing of foodstuffs;

    Whereas, in establishing maximum residue limits for residues of veterinary medicinal products in foodstuffs of animal origin, it is necessary to specify the animal species in which residues may be present, the levels which may be present in each of the relevant meat tissues obtained from the treated animal (target tissue) and the nature of the residue which is relevant for the monitoring of residues (marker residue);

    Whereas, for the control of residues, as provided for in appropriate Community legislation, maximum residue limits should usually be established for the target tissues of liver or kidney; whereas, however, the liver and kidney are frequently removed from carcasses moving in international trade, and maximum residue limits should therefore also always be established for muscle or fat tissues;

    Whereas, in the case of veterinary medicinal products intended for use in laying birds, lactating animals or honey bees, maximum residue limits must also be established for eggs, milk or honey;

    Whereas potassium nitrate, potassium dl-aspartate, potassium glucuronate and potassium glycerophosphate should be inserted into Annex II to Regulation (EEC) No 2377/90;

    Whereas, in order to allow for the completion of scientific studies, florfenicol and moxidectin should be inserted into Annex III to Regulation (EEC) No 2377/90;

    Whereas, in order to allow for the completion of scientific studies, the duration of the validity of the provisional maximum residue limits previously defined in Annex III of Regulation (EEC) No 2377/90 should be extended for albendazole sulphoxide and carprofen;

    Whereas it appears that maximum residue limits cannot be established for metronidazole because residues, at whatever limit, in foodstuffs of animal origin might constitute a hazard to the health of the consumer, whereas it should be inserted into Annex IV to Regulation (EEC) No 2377/90;

    Whereas a period of 60 days should be allowed before the entry into force of this Regulation in order to allow Member States to make any adjustment which may be necessary to the authorisations to place the veterinary medicinal products concerned on the market which have been granted in accordance with Council Directive 81/851 /EEC (3), as last amended by Directive 93/40/EEC (4) to take account of the provisions of this Regulation;

    Whereas the measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Veterinary Medicinal Products,

    HAS ADOPTED THIS REGULATION:

    Article 1

    Annexes II, III and IV of Regulation (EEC) No 2377/90 are hereby amended as set out in the Annex hereto.

    Article 2

    This Regulation shall enter into force on the 60th day following its publication in the Official Journal of the European Communities.

    This Regulation shall be binding in its entirety and directly applicable in all Member States.

    Done at Brussels, 18 March 1998.

    For the Commission

    Martin BANGEMANN

    Member of the Commission


    (1)  OJ L 224, 18. 8. 1990, p. 1.

    (2)  OJ L 53, 24. 2. 1998, p. 3.

    (3)  OJ L 317, 6. 11. 1981, p. 1.

    (4)  OJ L 214, 24. 8. 1993, p. 31.


    ANNEX

    A.

    Annex II is modified as follows:

    1.

    Inorganic chemicals

    Pharmacologically active substances(s)

    Animal species

    Other provisions

    ‘Potassium nitrate

    All food producing species

     

    Potassium DL-aspartate

    All food producing species

     

    Potassium glucuronate

    All food producing species

     

    Potassium glycerophosphate

    All food producing species’

     

    B.

    Annex III is modified as follows:

    1.

    Anti-infectious agents

    1.2.

    Antibiotics

    1.2.11.

    Florfenicol and related compounds

    Pharmacologically active substance

    Marker residue

    Animal species

    MRLs

    Target tissues

    Other provisions

    ‘Florfenicol

    Sum of florfenicol and its metabolites measured as florfenicol-amine

    Fish

    1 000 µg/kg

    Muscle and skin in natural proportions

    Provisional MRLs expire on 1.7.2001’

    2.

    Antiparasitic agents

    2.1.

    Agents acting against endoparasites

    2.1.1.

    Benzimidazoles and pro-benzimidazoles

    Pharmacologically active substance

    Marker residue

    Animal species

    MRLs

    Target tissues

    Other provisions

    ‘Albendazole sulphoxide

    Sum of albendazole, albendazole sulphoxide, albendazole sulphone and albendazole 2-amino sulphone, expressed as albendazole

    Bovine, ovine, pheasant

    1 000 µg/kg

    Liver

    Provisional MRLs expire on 1.1.2000’

    500 µg/kg

    Kidney

    100 µg/kg

    Muscle, fat

    Bovine, ovine

    100 µg/kg

    Milk

    2.3.

    Agents acting against endo- and ectoparasites

    2.3.1.

    Avermectins

    Pharmacologically active substance

    Marker residue

    Animal species

    MRLs

    Target tissues

    Other provisions

    ‘Moxidectin

    Moxidectin

    Equidae

    50 µg/kg

    Muscle

    Provisional MRLs expire on 1.1.2000’

    500 µg/kg

    Fat

    100 µg/kg

    Liver

    50 µg/kg

    kidney

    4.

    Anti-inflammatory agents

    4.1.

    Nonsteroidal anti-inflammatory agents

    4.1.1.

    Arylpropionic acid derivative

    Pharmacologically active substance

    Marker residue

    Animal species

    MRLs

    Target tissues

    Other provisions

    ‘Carprofen

    Carprofen

    Bovine

    1 000 µg/kg

    Liver, kidney

    Provisional MRLs expire on 1.1.2000’

    500 µg/kg

    Muscle, fat

    Equidae

    1 000 µg/kg

    Liver, kidney

    50 µg/kg

    Muscle

    100 µg/kg

    Fat

    C.

    Annex IV is modified as follows:

    List of pharmacologically active substances for which no maximum levels can be fixed

    ‘Metronidazole.’


    Top